Friday November 27 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

AspenBio Pharma

AspenBio Pharma, Inc. is an emerging biotechnology company engaged in the discovery, development, manufacture, and licensing or marketing of products primarily for animal healthcare. Founded in August 2000, and headquartered in Castle Rock, Colorado, we leverage our proprietary knowledge and technology towards the development of novel patented or patentable products we believe have substantial market potential. As a significant supplier of human antigens, we manufacture and market approximately 30 antigen products primarily for use as controls by diagnostic test kit manufacturers and research facilities, to determine whether diagnostic test kits are functioning properly. While generating modest, but substantially all of our revenues from this antigen business, we have been actively advancing the development of novel animal reproduction products for large worldwide markets. We currently have a growing product pipeline including novel recombinant hormones and diagnostic tests in development. We also recently initiated our first Food and Drug Administration ("FDA") application with an Investigational New Animal Drug Application ("INADA") filing for one of our new recombinant hormones. By focusing primarily on veterinary medicine, we gain several competitive advantages. First, since the FDA approval process for animal products is often less costly and time-consuming than that for human products, our research and development costs are substantially reduced and the timeline to product launch is shortened. Second, we believe animal healthcare represents an area of significant market potential with less market competition as compared to the human market. Third, we are able to focus our research and product development resources on improving animal reproduction providing significant new economic and efficiency benefits in large well-developed as well as underdeveloped markets worldwide. Fourth, we are able to focus on fully exploiting what we believe is the significant market potential of a totally new class of reproduction hormones via our patented "single-chain gonadotropin" technology which we believe offers a number of significant cost and performance advantages in numerous non-human mammalian species of economic importance, over conventional native hormone products currently available. Success for us will depend on our ability to develop and commercialize new products. We are currently focused on completing development of, and bringing six novel products to market. Three of these products provide solutions to improve bovine reproduction, two of these products provide unique solutions for equine reproduction and one human diagnostic product provides a totally new method of assisting physicians in the diagnosis or rule out of appendicitis. We have applied for patent protection on products where they are not already patented under acquired licensed rights.


Contact Details:
1585 South Perry Street
Castle Rock
80104
United States of America
Tel:303-794-2000
Fax:303-798-8332
Email:lmurray@aspenbiopharma.com
WWW:

www.aspenbioinc.com/




Press Releases on AspenBio Pharma:

BioPortfolio Logo
Reportlinker Adds Point of Care Diagnostics 2010 and Beyond: Rapid Testing at a Crossroads 5th November, 2009 Reportlinker
NEW YORK, Nov. 5 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Point of Care Diagnostics 2010 and Beyond: Rapid Testing at a Crossroads

BioNews Results for AspenBio Pharma:

AspenBio Pharma, Inc. - Medical Equipment - Deals and Alliances Profile - new report released
PR inside:  Nov 16 2009 4:58AM Matching: aspenbio pharma
AspenBio Pharma, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new report
PR inside:  Nov 16 2009 4:46AM Matching: aspenbio pharma
AspenBio to Present at the Lazard Capital Market 6th Annual Healthcare Conference
Freshnews.com:  Nov 13 2009 6:41PM Matching: aspenbio pharma
AspenBio Pharma Inc.-Financial Company Report - research report released
PR inside:  Oct 30 2009 10:53AM Matching: aspenbio pharma
AspenBio Pharma Down 9.8% Since SmarTrend's Sell Recommendation
Individual.com:  Oct 29 2009 9:10AM Matching: aspenbio pharma
Promote your company here: BioNewsCast - Press Release Distribution

View more AspenBio Pharma news.

AspenBio Pharma Clinical Trials:

[Trial of device that is not approved or cleared by the U.S. FDA]

AspenBio Pharma Patents:

US Patent No.Title
7501256 Methods and devices for diagnosis of appendicitis
7393696 Bovine pregnancy test

AspenBio Pharma (APNB.OB) Financial information Links from Barchart

APNB.OB Quote from from Barchart.com
APNB.OB Chart from from Barchart.com
APNB.OB Profile from from Barchart.com
APNB.OB Opinion from from Barchart.com

View more AspenBio Pharma finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 267 times since April 2007, the link to the organisation's website has been followed 52 times

Search for more companies in Castle Rock

Search for more companies in



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for AspenBio Pharma

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.